Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases

Pikoulis, Emmanouil; Margonis, Georgios Antonios; Andreatos, Nikolaos; Sasaki, Kazunari; Angelou, Anastasios; Polychronidis, Georgios; Pikouli, Anastasia; Riza, Elena; Pawlik, Timothy M.; Antoniou, Efstathios

doi:10.21873/anticanres.11040

Cited by 23 publications

(13 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CRC that carry BRAF mutations have been associated with poor prognosis. BRAF mutations are more frequent in right colon tumors, poorly differentiated, with a mucinous histology and infiltrating lymphocytes that are usually MSI-High [ 30 ]. Approximately 8% of CRC carry the distinct BRAF V600E mutation.…”

Section: Braf Mutationsmentioning

confidence: 99%

Current and future biomarkers in colorectal cancer

Zarkavelis¹

2017

aog

View full text Add to dashboard Cite

Colorectal cancer (CRC), one of the leading causes of death among cancer patients, is a heterogeneous disease and is characterized by diversions in multiple molecular pathways throughout its evolutionary process. To date, specific mutations in RAS and RAF genes are tested in everyday clinical practice along with mismatch repair gene deficiency, serving either as prognostic or predictive biomarkers, providing information for patient risk stratification and the choice of appropriate therapy. However, ongoing studies are focusing on the potential role of recently discovered genetic and epigenetic alterations in the management of CRC patients and their potential prognostic or predictive value. To overcome the problem of tumor heterogeneity as well as the practical obstacles of access to tumor tissue, and to achieve real-time monitoring of disease and therapy efficacy, liquid biopsies constitute a novel technology worth exploring. CRC screening and management is entering a new era where molecular testing will be applied to genomic material extracted from easily accessible bodily fluids.

show abstract

Section: Braf Mutationsmentioning

confidence: 99%

Current and future biomarkers in colorectal cancer

Zarkavelis¹

2017

aog

View full text Add to dashboard Cite

show abstract

“…Several research groups have provided evidence that two proto-oncogenes, KRAS and BRAF , are associated with resistance to chemotherapy and poor prognosis [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ], as confirmed by the survival analysis of the BRAF mutated CRCLM included in the TCGA cohort ( Figure 4 B).…”

Section: Resultsmentioning

confidence: 83%

Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma

Lopez

Boggio

Ferrero

et al. 2018

IJMS

View full text Add to dashboard Cite

Despite the significant recent achievements in the diagnosis and treatment of colorectal cancer (CRC), the prognosis of these patients has currently plateaued. During the past few years, the opportunity to consider multiple treatment modalities (including surgery and other locoregional treatments, systemic therapy, and targeted therapy) led to the research of novel prognostic and predictive biomarkers in CRC liver metastases (CRCLM) patients. In this review, we seek to describe the current state of knowledge of CRCLM biomarkers and to outline impending clinical perspectives, in particular focusing on the cutting-edge tools available for their characterization.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Differences in outcome are undoubtedly related not only to LT, but also strict patient selection. To this point, patients with poor prognostic risk factors for recurrence and survival after CLM resection were excluded from the SECA study 59,60. More recent data from the NORDIC VII study have suggested results in favor of LT over standard chemotherapy for unresectable CLM in light of the only 9% 5-year OS among patients receiving firstline combination chemotherapy only 61.…”

mentioning

confidence: 99%

Liver transplantation for unresectable colorectal liver metastases: A systematic review

Moris

Tsilimigras

Chakedis

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

The use of liver transplantation (LT) for liver metastases attempted in the early 1990's was associated with poor perioperative outcomes and unacceptably low overall survival. Recently, there has been renewed interest in LT as a treatment option for colorectal liver metastases (CLM) in countries where organ supply is high. To date, no meticulous analysis about the efficacy, safety and outcomes of LT in CLM patients has been published. We present the first systematic review on the subject.

show abstract

Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases

Abstract: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.

Cited by 23 publications

References 37 publications

Current and future biomarkers in colorectal cancer

Current and future biomarkers in colorectal cancer

Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma

Liver transplantation for unresectable colorectal liver metastases: A systematic review

Contact Info

Product

Resources

About